全文(pdf 161MB) - アプライド・セラピューティクス学会
Contents
1.2.
3.
4. K
5. aw H S
6. DVD
7. S1 4 lt
8. TD M
9. El NPO
10. S2 3
11. os A i og Sti
12. DPC 25 7 The 4th Annual Meeting of Japanese Society for Applied Therapeutics 7 28 2 1 10 30 11 15 fil
13. BHAI A vty ES1 1 ME KRP Y OD PK PD
14. EBM EBM EBM
15. Hi 2 6 ER 28 AAR EO HO IWRC IS W BP 20
16. ES1 4 Ofe Rt
17. Evidence Based Medicine HR
18. FAPA
19. 6 PBL
20. PD2 1 OTC OTC
21. PD2 2 23
22. 2011 10 2013 4 277 77 53 24 69 9 16 7 278 44 2 34 21 13 705 91
23. k PMDA
24. EO EM BA SADT DORM MER ERAT 5 quality of life QOL
25. I
26. opt ES1 3 ORKE PMDA PMDA
27. 1 1 2
28. CDTM CDTM 23 5
29. ra p S2 2 Sth PH HM Problem based Lean ing PBL
30. S1 3 ORE F TREE BRI
31. Web 12 ICH Med DRA J Web i BR Web Tes
32. 3 ae RN S3 3 HES T A wa Of 65
33. RN i oan ha no oe 3 He SNS BERETS LACE
34. S1 2 AT AE WRA collaborative care 1
35. GT S3 2 Of 16 3
36. 1 5 HIV 2 lt HIV AIDS HIV QOL 1
37. E JD 1 2 OIA FR MF k F BR RE JAP REE Wa WIL AF RP
38. ul Hit Hit RP 2 5 lt lt OAR See PRT WER
39. EBM 2 4 il
40. PD1 3 3 AH ett 2011
41. wandering pacemaker 88 2012 1 Omg 2012 12 137U L 168 470U L 1 196U L wandering pacemaker
42. Eh S2 4 aie A I 18 6 6 42 14 8
43. 1 4 HIV 1 HIV AIDS 2012 2 4 1980 E HIV AIDS 2001 2003 2004 15 ee 2005 2007 5 es 1 580 HIV
44. 2 HCU 1 3
45. 15 00 15 00 16 00 15 00 16 00 nang a ER l BAIRRI SORSAS A lt lt 16 00 17 00 18 00 The 4th Annual Meeting of Japanese Society for Applied Therapeutics GH
46. 18 TDM m mp o A vty A vty ON PD1 1
47. 2 1 ES 23 CKD T E KARTER 2 2 2HR BT chronic kidney disease CKD GFR
48. astellas Leading Light for Life www astellas com jp We Sawal gt T20 T25 mu BEE 0120 381 99
49. whole task approach 4C ID 24 5 194 48 PBL 3 1 2 SOAP 25 4 160 825
50. Sil BER 85 5 368C 105 59 90 SpO 87 SpO 2
51. 2006 6 2012 6 50 PIR 1975 ATHA 1985 1987 MR T DI Drug information
52. 24 Ch 5 83 7 953 90 7
53. 1 26 Goodman amp Gilman s The Pharmaco logical Basis of Therapeutics 12th Edition Mac Graw Hil 2011 Appendix II Design and Optimization of Dosage Regimens Pharmacokinetic Data 4 H 3
54. problem lists 4 1 A4 1 RAT readi ness assurance test NEJM gt 3 1
55. 2 Academic Detailing A D PMDA
56. Medline 15 26 CIERRE ARS binding sensitive B P Lae H 6 17 B P 33
57. GE OTC
58. ER 5A Bek EWH
59. IL 1 Ck BRIM T ARROAR OS E 2 S1 5
60. gt S2 1 R ORN
61. SOAP SOAPMF 55 SOAPMF 2011 SOAPMF SOAP SOAP 2011 2 10 35 SOAP lt www applied therapeutics org pagel2 html
62. POmg 30 49mL min 15mg 1 1 11 2 09 9 596 537 696 196 2 85 2 796 124 796 7 1 6 1 1 92 1 1 396 8 1 fi 196 H 0 10 H eee H 0 2 9 AR x 0 1596 15 5 1 05 Ft 0 68 F 0 23 0 O 0196 BOs LE DROSMICHAILKRS eh PRS A BA ROMERO DRIMERDD SONS 2 ALT GPT AST GOT 0 1 1 9 BIS
63. BT Si W RT RRAK ME WP AR AF RI AT RTP EH OK
64. 1 ul 0 9000 11 000 2000 2013 6 21 6 25 ACK 2 2000 3 1 4 7 27
65. 2 KER
66. W RR RLI RF ARI AP RP Bek The 4th Annual Meeting of Japanese Society for Applied Therapeutics 1 3 2 BT R DE RE SEB SI 1 4 HIV 1 1 5 HIV 2 7A278 1 2 1 15 00 16 30 BG 2 1
67. S1 1 2010 9
68. gt Be ee 2 ET 2 2 Wandering Pacemaker 2 ORE 2 pE 2 2 3 CKD RR FI 2 4 BF PH AI OT The 4th Annual Meeting of Japanese Society for Applied Therapeutics 2 5 2 6 2 7
69. Hb PD MBDD ES1 2 1 GCP Good Clinical Practice
70. JR JR AHSA BIA URES The 4th Annual Meeting of Japanese Society for Applied Therapeutics 1 7 27 17 45 oe Ty a tH Fay pO ch i Kli 1 ag 4 H 1 ae 2 a
71. 1 1 3 4 PBL 4 PBL 5 1 120 So
72. S AROLE 8 1 CYP3A4 CYP2J2 BD aei 2 eee LUA St John s Wort
73. ES1 5 OL
74. IRB 3 1 2 2 3 3
75. REP Fe PUMAN BITZUA prea Bt Eee LUTTE AS 15 00 16 30 0032600 TEE EE SEL ORR Ne 9 RAIE RELY 9 1 16 30 17 30 EBM RA ASR REY 17 45 The 4th Annual Meeting of Japanese Society for Applied Therapeutics
76. Atorvastatin ATV CKD ATV Rosuvastatin ROS 2006 11 2011 10 CKD 268 ATV ROS CKD 3a 3b 3 29 KER ATV 64 1 1 mg dL 55 1 4 mg dL
77. SOAP SOAP ES Mt W st a 13 2 ee eh asp 1974
78. Dmab NCCN ASCO 2012 4 Dmab BP zo HE MEDLINE Cochrane Library denosumab BP OS SRE R AE Co chrane Review Manager 5 2 F 118 8 Dmab BP OS SRE AE RR 099 95 0 93 1 05 0 83 0 79 0 87 0 96 0 68 134
79. JCE Xa ID VT it 10mg 15mg Xarello 2 4 9 530 0001 http www bayer co jp byl DOSEN One ak BES EE t
80. l S OES Hmsor H H ild Pugh B C 1 5mL min _ a 8 Jb 8 ag terial 5mg 1 1 3 FP x TF P450 3A4
81. XGA 1024x768 Windows 2007 XGA 1024x768 Dsub 15 The 4th Annual Meeting of Japanese Society for Applied Therapeutics an a al T 162 8666 8 1 TEL 03 3353 8111 1 5 5 A2 8 2 74 Z5 71 81
82. 6 34 15 441 ra FE BJ ii jE BJ
83. ES2 EBM KFE EBM EBM EBM EBM EBM Evidence Based Medicine EBM EBM EBM
84. ORE BE 7 28 2 1 4 12 15 13 15 7A278 1 3 13 45 14 45 Az Ro 7A278 1 3 15 00 16 00 OB The 4th Annual Meeting of Japanese Society for Applied Therapeutics 7 28 8 3 9 30 10 30 7 amp
85. 2004 FDA Model Based Drug Develop ment MBDD MBDD PK PD PK PD in vitro PK PD PK PD PK PD PD MoA Mode of Action
86. MRR
87. emee orc 50mg 100mg HEL 100mg EEI 40mg HET 100mg EEI X A OE tkrar utas Nemo 0120 517 215 r wert 2013 6 2 om d Eo NORMALIZE VASCULAR Ca SHEE REAR kmen J a J R R 2 5mg Sk5mg 8k10mg OD k 2 5mg OD 5mg OD k 10mg e eee
88. gt RJE 2 RI 4 CA Sa yy OBE FX BE MS O 8 t SO 2013 2 lueuelddns
89. PowerPoint PC PC PC USB EX PC AC E 2 3 1 1 PC PC
90. 10 fay E 1 1 1 HTE sey PC PC Windows PC 10 PC PC
91. EB E ES3 19 24 30 ECHIALITZC EAA 24 26 1 25 4 609
92. 2 d 1 8g 1 1 1 2g 1 1 1 2 1 3 4 LDL
93. 1 2 283 D B C O 9 The 4th Annual Meeting of Japanese Society for Applied Therapeutics 1 7 27 9 00 10 00 11 00 12 00 13 00 14 00 15 00 16 00 17 00 18 00 1 3 1 2 9 0016 30 9 50 10 00 10 00 10 45 sn ERRE 1045 255
94. 20 12 20 7 1 2 5 25 2 10 10 WVG
95. 7 28 8 3 14 00 15 00 fil 7 58 2 3 15 00 16 00 7 27 1 1 1 15 30 16 30 1 1 Web ORE fl KEE A AMEE WH FR WE WKY Sik E I 1 2 2 OAA FO EAER WME HY
96. ERENER RCN BK MA EC OK BF EF ME TE S R WEB B TBL 7 28 2 1 3 11 20 12 05 3 3 2 3 3 3 4 8 BR Xa 1 BA TER
97. 151 8589 ae 3 22 7 2013 1 meiji Meiji Seika 2013 5 CD wa JONUVIG E ae r AE 100ne MSD MSD niin R eee ne 7102 8667 1 13 12 http www msd co jp 2011 6 JAN11AD008 0616
98. The 4th Annual Meeting of Japanese Society for Applied Therapeutics 1 1 7 27 9 00 16 30 7 28 8 30 16 00 2 3 4
99. KENI FE OTC 2011 12 A 2012 12
100. Lid 1 Eg 1 D dimer I 3 2 9 ORT EE lt 1 Cmax tmax AUC
101. 1 1
102. orme OAncaron PAN DS Ft 100 SAncaron Pad II 75O 100 150 JE CMR o 7163 1488 SANOFI wg 2012 10 JP AMD 12 10 06 20 EPA DHA J Do F J 2g 3 1
103. 2011 11 FPHT TDM FPHT TDM 2 FPHT 2 51 PK TDM PK PHT Alb Alb Tanaka FPHT PK PPK Alb 2 1 5 2 Vd 064 L kg 1 3 L kg FPHT 2 4 Vd 1 2 L kg PPK Alb
104. K BA h AE WRA The 4th Annual Meeting of Japanese Society for Applied Therapeutics S1 3 One Sl 4 S1 5 7 58 2 1 9 00 10 30 SM S2 1 S2 2
105. 51 1 5 Alb 8 1 ug mL 10 ug mL 59 mg kg 93 mg kg PPK Alb TDM 2 2 Wandering Pacemaker OBE pH 2
106. FIPS 2B0 A9ML minDBE clk 10mg 1 2 15 29mL min 1 1 Te 1 cee all 3
107. OTC PD2 2 Fi 7 27 1 1 12 30 13 30 OU 7A278 1 2 1 2 12 30 13 30 CKD Key word The 4th Annual Meeting of Japanese Society for Applied Therapeutics 7 28 2 1 93 12 15 13 15
108. 2 a e eaten 2012 7 2013 3 2012 7 2013 2 13 4 1 2013 3 4 4 2 1
109. LDL 3 4 3 g 4g 848 91 9 6 2 59 2013 1 7103 8668 12 10 ore 60mg E a peg g 0120 108 932 24
110. 4 16 13 0120 062 256 OMNI105A EJ Wa 827 7 e mailinquiry japan sandoz com URL http www sandoz jp 2011 5 BARA 1867 1916 43 1916 49 H2 O ym ft 5 10 0v 5 10 PO7 0 3532 mmase maT er 7101 8444 1 27 TEL 0120 20 4527 http wwwtaiho co jp 2013 1 2013 6
111. Of Ho ES1 5 TH IRR KEIR PAER LY TY TEHAS 7 57 1 1 16 30 17 30 Be ES2 EBM OHR RKE 7 28 2 1 3 14 00 14 50 SR Beit ES3 7A278 1 1 1 10 45 12 15 S1 1 F S1 2
112. 2 3 1 2010 2 100 2
113. ARAN CH 3 15mg L min 10mg 0 EEE 8 50 7 8 40 6 396 MR24 68 23 3 6 1 8 2 896 2 796 2 E 14 2 296 12 1 9 FH 1 1 796 9 1 496 7 1 96 7 1 7 1 196 H 1 196
114. 1 ERRE E RRA RAR UX 1 VX 2 Ra CKD Key word EH BLU PYF RNAS 13 45 15 15 BSM Ry i 13 45 14 45 1 aS zaa ZDEENTE RT EBER RIERA ERTO yav EN DY BEE MIU EAE es Asete gt 9 ci MEE EE RBNA
115. 571 8580 2 11 http www towayakuhin co jp 2013 5 mo ocr 1 IRK 1 p ft JJ 4 3 24 oes SANE J 4 F 7 E 5 BE Ra bx
116. 6 8 1 E RIRE B1 2 g 27 3 28 3 6 The 4th Annual Meeting of Japanese Society for Applied Therapeutics E 1 1
117. p 0 013 ROS 6 7 1 3 mg dL 6 7414 mg dL p 0520 eGFR ATV 511 78 mL min 1 73m 618 13 3 mL min 1 73m p 0 015 ROS 477 70 mL min 1 73m 525184 mL min 1 73m p 0 326 CKD ATV CKD 3 ROS ATV ra 2 4
118. 97 7 953 1 1 Web ORE Kat He ti DEBE WBA Bi 8 i EA CRO AW 24 1
119. P Ry Ry EF BQ RE ME DREE HR R SA AE WA The 4th Annual Meeting of Japanese Society for Applied Therapeutics 7 28 2 1 16 OO 16 30 BR C 1 9 OU C 2
120. seo n FET abl lt T IM QH och A ISH KA WENA YI BNI NI E IE 4 6
121. AR eh ER SOAP SOAP SOAPMF SOAPMF 1 4 S O A P POS SOAP
122. BE SE ry ra J E JD 4 C 2 SOAP D SOAP E fag mi WE Hfr HU H EH U
123. 3 4 E PR FRE ME DREK eA IDB B 1990 2005 627 14 Y I JE F 147 58mg 2010 470 60 150 1 419 58 251 HEJL K 17 I
124. AE BP RR O70 0 87 0 90 wt Ca Dmab RR 2 11 8 Dmab BP OS SRE QOL Dmab Ca Dmab Dmab Ca Ca D Dmab BP OS AE SRE 2 7 TBL EZO A 4 SGD Team based learning TBL 1
125. H24 10 16 12 S3 1 OR
126. 7 CHE Lo 9 E 2500 2 H AST 232 IU L ALT 314 IU L cif IER 26 1875 0 90 H CRET 1 bizs fit Xa 1 1625 2 3 Xa 020 0 25U ml HEIR 38 D dimer VE AY Te A CT Cla hii ze HEERO HERS 1
127. OAH DPC 65 10 23
128. Fa K 7 27 1 1 10 00 10 45 il 7 57 1 1 1 13 45 15 15 FORRAR C M ES1 OF ES1 2 ES1 3 The 4th Annual Meeting of Japanese Society for Applied Therapeutics ES1 4
129. OR AMEE SH Zt FE S2 3 S2 4 The 4th Annual Meeting of Japanese Society for Applied Therapeutics 7 28 8 2 1 3 9 00 10 30 BR S3 1 ORE S3 2 Ofk im S3 3
130. 7A278 1 2 1 1 13 45 14 45 HH PD1 1 PD1 2 PD1 3 ORR o AH RL Arr Sea Bear The 4th Annual Meeting of Japanese Society for Applied Therapeutics 7A238 2 1 15 00 16 00 PD2 1
131. 12 30 13 30 3 2 5 7 28 13 30 14 00 1 4 The 4th Annual Meeting of Japanese Society for Applied Therapeutics 6 27 17 45 7 1 2 3 4 5 1
132. Bek 1 55C 20ml 10 19 22 25 4
133. Ley 2007 10 2 2 1 2 WT W 2 FPHT PHT PHT
134. 80 16 1 2 4 160 12 80 4 1 New Englan Jour nal of Medicine NEJM 5 SGD 3 2 3 SGD 2 1 SGD 1
135. 25 7 1 5 Supplement 22 4 lt Japanese Journal of Applied Therapeutics ISSN 1884 4278 Japanese Society for Applied Therapeutics Vol 5 Supplement July 2013 ED The 4th Annual Meeting of Japanese Society for Applied Therapeutics wep 0 15 7 8 2 Wey mH ill The 4th Annual Meeting of Japanese Society for Applied Therapeutics MBE CODE DC 3 SF a aed E vnc coset tewdea Ei i 4 ey eA tot mcs g a sw saere ee denne e eee nnn 6 SPORE 8 9 E e a eae ie ee ee eens 10 FEU ANE ci eee eee ree ee ce ee er ee eer ee ere eT 12 ess eae terns neces ao me SI E a 13 mid ix NM eee eed 26 EEH S E E 26 A aS E E E E 27 SI 30 PAN A FPS octet asd rca ence at
136. PD1 2 5 2000 4 13 DPC 10
137. 2 7 28 1 2 3 1 8 30 16 00 900030 900030 3 9 00 9 30 0 30 i EA File RENA EEE ES IGS ACS AM es 10 00 10 30 11 15 FA
138. E 376 27 4 3 21 BI 3 6 1 C 1 ow OW 2
139. PT INR ce fells aPTT 2 1 PT INH TARI 0 AA ne 8 PT INR EDEN AR SO 24 PT INR
140. Xa 1 2 BA TEM 34 6 16 120 70mmHg 63 SpO2 100 TEO MIRZO D dimer 10 7ug ml ko S 11 DI
141. gt The 4th Annual Meeting of Japanese Society for Applied Therapeutics 50 MSD Meiji Seika 4 25 7 4 fi El Mall
142. 9 06 6105 5816 http med sawai co jp oncology I 2013 6 f a a we p TS 7 me 2 ade ty Me f 4 Pioneering the future Gaal a 2 BS 5mg 10mg Somatropin BS S C Injection 5mg 10mg SANDOZ E BS 5mg 10mg 5 10 Omnitrope Pen 5 220AFBZX00240000 10 220AFBZX00241000
143. Windows PC 10 PC i o PowerPoint a PC PC The 4th Annual Meeting of Japanese Society for Applied Therapeutics PC USB PC AC E 1 10 7 3 E
144. aes 11 00 SE 11 20 12 05 3 12 00 3 Uh 4 13 004 13 3044 00 14 00 1400 1450 3 14 00 15 00
145. een nd ae cee eas 36 39 47 Wa hice ae See eet ES tr re er Ea ee ot 48 The 4th Annual Meeting of Japanese Society for Applied Therapeutics 25 7 27 28 A 2 4
Download Pdf Manuals
Related Search